Shares of Eraaya Lifesciences surged 5% to reach a new all-time high of ₹2,767.40 on the BSE on Tuesday following the company's announcement regarding the suspension of Robin Raina, Chairman and CEO of Ebix, after its acquisition of the latter.
In a typical activist campaign, the activist threatens to launch a proxy fight unless the board of directors agrees to take certain actions to increase shareholder value, such as selling off company assets or replacing the CEO. Increasingly, however, there are fewer proxy fights.
Eraaya Lifespaces share price was locked in the 5-per cent upper circuit for the 14th straight trading day on the BSE. It has zoomed 102% in the past 3 weeks
Increasing demand for automation and digital transformation in the insurance industry and growing focus on data analytics and artificial intelligence are...
NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common shares of Sono Group N.V. Sono Group N.V.'s securities were suspended on July 21, 2023, and have not
NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common shares of Sono Group N.V. Sono Group...
Retains Dominant Leadership Role in Foreign Exchange, Inward and Education Money Remittance SectorsAddition of five international airports with presence...
Infrared Cameras Holdings Inc (MSAI) is up over 137% at $6.23. The following are some of the other stocks making big moves in Thursday's pre-market trading..
Infrared Cameras Holdings Inc (MSAI) is up over 137% at $6.23. The following are some of the other stocks making big moves in Thursday's pre-market trading..
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in pre-market trading. Here are some other stocks moving in pre-market trading.
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.